Skip to content

Natera

US · NTRA #387 by market cap Listed 2015
273.40 -16.52 -5.70%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 21.21 Expensive vs history 80th percentile
5-year average 15.26 · #37 of 41 in Diagnostics & Research
P/E ratio -244.11 Cheap vs history 4th percentile
5-year average -63.67 · forward -373.73
P/S ratio 13.63 Expensive vs history 78th percentile
5-year average 10.47 · forward 11.41 · #37 of 44 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
Natera (NTRA) 39.64B -244.11 21.21 0.00%
Thermo Fisher Scientific (TMO) 248.08B 35.31 4.53 0.27%
Danaher (DHR) 155.03B 36.12 2.89 0.69%
IDEXX Laboratories Inc (IDXX) 53.28B 45.57 28.50 0.00%
Agilent Technologies (A) 48.04B 33.61 6.52 0.59%
Waters (WAT) 43.29B 184.29 2.83 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★☆☆☆ Fair value233.15 Economic moatNarrow UncertaintyHigh

Trading 14.7% above Morningstar's fair value estimate.

Fair value

Natera Inc receives a 2-star quantitative star rating, indicating our belief that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 24% premium over our quantitative fair value estimate of $233.15 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's lack of profitability undermines our fair value estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of 0.3%, which falls in the bottom 30% compared with global peers. The earnings generated by the company relative to its share price is concerning, which contributes to our view that shares are overvalued.

The firm's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 4.1%, a core component of valuation, ranks in the bottom 10% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:26 · For reference only, not investment advice and not tailored to your situation.

Natera discussion 0 comments

Add a comment